Walgreens Lost to CVS in a Boardroom, Not a Store Aisle
Walgreens kept more foot traffic than CVS right up to the end - 50% of the two chains' visits. It still got taken private in a roughly $10 billion fire sale. The reason wasn't worse stores. It was one capital-allocation bet that went 13x bigger at CVS.
Comes with a free Counterfactual Timeline Builder template.
On the last day of February 2024, the entire market value of Walgreens Boots Alliance - one of the most recognizable storefronts in America, $147.658 billion of annual sales running through its registers3 - was about $15.2 billion.3 The company sold more than nine times its own worth in goods every year, and the stock market valued the whole thing at less than a fifth of a single quarter's revenue. Eighteen months later it was gone from public markets entirely, taken private by a buyout firm for roughly $10 billion.7 The strange part: through this whole collapse, Walgreens was still winning the part of the contest everyone assumes it lost.
The official story is that CVS simply out-operated Walgreens in retail pharmacy - better stores, better execution, more customers walking in. Almost none of that is true. Between early 2023 and late 2024, Walgreens held the larger share of the two chains' drugstore visits, growing from 49.2% to 50.4% of them, while CVS climbed from 41.9% to 44.0%.8 More people kept choosing the door with the script logo. Walgreens didn't lose at the register. It lost in the boardroom.
Two companies read the same memo and bet very different amounts
By the late 2010s, both chains had reached the same conclusion: the corner drugstore was a melting ice cube. Margins on dispensing pills were under permanent pressure, Amazon was circling, and the real money in American healthcare was moving toward whoever sat closest to the insurance dollar. The thesis was identical. The size of the wager was not.
CVS made one transformative bet. In November 2018 it closed its acquisition of the health insurer Aetna - a deal that valued Aetna at roughly $70 billion in equity and about $78 billion including assumed debt, financed in part by issuing some $45 billion of new debt.1 Overnight, CVS stopped being a pharmacy chain that also sold cards and candy. It became a managed-care company that happened to own stores: an insurer, a pharmacy-benefit manager, and a retail footprint, all feeding the same revenue river. That is structural diversification - the kind that doesn't depend on the drugstore aisle to make money.
“$145.00 in cash and 0.8378 CVS Health shares for each Aetna share.”2
Walgreens chased the same destination - own more of the healthcare dollar - through a far smaller and far flimsier vehicle. It invested $1 billion in the primary-care operator VillageMD in 2020, then sank another $5.2 billion in 2021 to take a 63% majority stake.4 The idea was to bolt doctor's offices onto drugstores: see a physician and fill the prescription under one roof. It was a plausible thesis. It was also a bet a thirteenth the size of CVS's, on building a clinic business from scratch rather than buying a profitable insurer outright - and clinics, it turned out, were not a business Walgreens knew how to run.
| CVS — Aetna | Walgreens — VillageMD | |
|---|---|---|
| What it bought | An established health insurer | A majority stake in a clinic startup |
| Capital committed | ~$78B including debt | Over $6B |
| What it added | Insurance + managed-care revenue | A loss-making care division |
| Operating fit | Adjacent revenue river | A business it had to learn to run |
| Result | Top U.S. pharmacy by Rx share | Written down, then sold off |
The clinic bet didn't just fail - it actively bled
Here is the mechanism, worked down. CVS's bet diversified its income away from the squeezed drugstore. Walgreens' bet did the opposite: it added a brand-new source of losses on top of the squeezed drugstore. The U.S. Healthcare division built around VillageMD generated $1.73 billion in operating losses in 2023 alone.5 Rather than buying a hedge against pharmacy decline, Walgreens had bought a second leak. By early 2024 it was retreating - planning to shutter 160 VillageMD clinics and exiting markets from Florida and Chicago to Boston, Rhode Island, and Las Vegas.5
Then came the reckoning. In fiscal Q2 2024, Walgreens took a $12.4 billion non-cash goodwill impairment on VillageMD - a formal admission that the asset it had paid over $6 billion to control was worth a fraction of that. After tax and the share owned by others, the charge attributable to Walgreens shareholders was $5.8 billion, driving a near-$6 billion quarterly net loss.4 Walgreens hadn't simply made a smaller version of CVS's bet. It had made an inverted one: the same strategic hope, structured so that being wrong cost money every quarter and then cost a fortune all at once.
The two paths landed in two different places. By 2025, CVS held over 26% of U.S. prescription-drug market revenue, the top pharmacy in the country with Walgreens behind it.6 Prescription dominance, notice, is not the same thing as foot traffic - Walgreens kept more visitors but moved fewer of the high-value managed-care dollars. And Walgreens itself ceased to exist as a public company: on August 28, 2025, Sycamore Partners completed its take-private, paying shareholders $11.45 per share for a total of roughly $10 billion, with the healthcare subsidiaries - VillageMD, Shields, CareCentrix - carved off to be sold separately.7
Isn't this just hindsight - CVS got lucky, Walgreens got unlucky?
The honest objection is that both bets were enormous gambles, and we're only calling CVS's the smart one because it worked. There's truth in that. The Aetna deal saddled CVS with roughly $45 billion of new debt1 and could plausibly have buried it under integration risk and regulatory pressure. Acquisitions of insurers are not free money. So the lesson is not 'always buy the bigger thing.'
But the asymmetry is real, not retrospective. CVS bought an asset that was already a functioning, profitable insurance business and slotted it alongside its existing pharmacy-benefit operation - revenue that does not require the drugstore to thrive. Walgreens bought a controlling stake in a business that was not yet profitable, in an industry it had never operated, and stapled it to the very retail footprint it was trying to hedge against. One company diversified its risk; the other concentrated it and called the concentration a pivot. The numbers that followed - top-of-market Rx share versus a $12.4 billion write-down and a private-equity exit - aren't luck. They're the shape of the two wagers, paid out.
When a core business is decaying, the instinct is to buy your way into the future. But the question that decides whether the bet saves you or sinks you is rarely 'is the thesis right?' - both Walgreens and CVS had the right thesis. It's 'does this asset add revenue that doesn't depend on the thing I'm fleeing, and can I actually operate it?' CVS bought a profitable insurer adjacent to a business it already ran. Walgreens bought a loss-making clinic chain in a discipline it had never practiced and bolted it onto the exact retail footprint it was trying to escape. The first diversifies risk. The second concentrates it while wearing the costume of diversification. Before you call an acquisition a pivot, check whether you'd survive being wrong about it - quarter after quarter, before the day the write-down arrives.
Walk into a Walgreens today and nothing looks like failure. The shelves are stocked, the line moves, and more people still pick that door than pick CVS's.8 That is precisely the point. The company that lost this race never lost the store. It lost the single decision that sat above the store - where to put the one big bet that the dying drugstore was supposed to fund. CVS spent $78 billion buying a different river to drink from. Walgreens spent $6 billion digging a deeper hole next to the one it was already standing in. The retail was a draw. The capital allocation was a rout - and in the end, only one of those gets to keep your name on the building.
When the decision above the business is the whole story
Counterfactual Timeline Builder
A one-page canvas that runs two histories side by side: what actually happened, and the alternative that died at the fork. You pin the divergence point, trace each branch forward, and name the assumption that decided which one came true. Blank, it disciplines hindsight into a testable counterfactual instead of a what-if; filled, it shows the story's road-not-taken with enough rigor to argue about.
The worked example unlocks with a subscription. See plans →
Sources
Where this comes from — the filings, records, and reporting behind it.
- 1CVS Health's acquisition of Aetna valued Aetna at approximately $70 billion in equity and approximately $78 billion including assumption of Aetna's debt; CVS financed the cash portion partly by issuing approximately $45 billion of new debt.
- 2CVS Health completed the acquisition of Aetna on November 28, 2018 (the 'Closing Date'); Aetna shareholders received $145.00 in cash and 0.8378 CVS Health shares for each Aetna share.
- 3Walgreens Boots Alliance FY2024 10-K (year ended August 31, 2024) shows Sales of $147.658 billion, gross profit of $26.524 billion, and an operating loss of $14.076 billion including a $12.701 billion goodwill impairment charge; aggregate market cap as of February 29, 2024 was approximately $15.2 billion.
- 4Walgreens invested $1 billion in VillageMD in 2020 and then sank $5.2 billion more in 2021 to become majority owner with a 63% stake; in fiscal Q2 2024 it recorded a $12.4 billion non-cash VillageMD goodwill impairment, resulting in a $5.8 billion charge attributable to WBA net of tax and non-controlling interest, producing an almost $6 billion net quarterly loss.
- 5Walgreens planned to shutter 160 VillageMD clinics (inclusive of a previously announced 60); VillageMD had already exited or notified patients of exits from Florida, Indiana, Chicago, Boston, Rhode Island, and Las Vegas; Walgreens' U.S. Healthcare division had generated $1.73 billion in operating losses in 2023.
- 6CVS Health held over 26% of U.S. prescription drug market revenue in 2025, making it the top U.S. pharmacy by market share, followed by Walgreens Boots Alliance.
- 7Sycamore Partners acquired Walgreens Boots Alliance, closing on August 28, 2025; shareholders received $11.45 per share in cash for a total deal value of approximately $10 billion (plus up to $3 per share from future sale of VillageMD businesses); Walgreens now operates as a private standalone company with Mike Motz as CEO, and its healthcare subsidiaries (VillageMD, Shields Health Solutions, CareCentrix) operate as separate businesses.
- 8Between Q1 2023 and Q4 2024, CVS's share of drugstore/pharmacy retail visits increased from 41.9% to 44.0%, while Walgreens' share grew modestly from 49.2% to 50.4%—indicating Walgreens retained a higher foot-traffic share even as its financial position deteriorated.